Comparative Pharmacology
Head-to-head clinical analysis: CIDA STAT versus HIBISTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIDA STAT versus HIBISTAT.
CIDA-STAT vs HIBISTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIDA-STAT is a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor that competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol levels.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. Active against susceptible gram-positive bacteria.
10 mg orally once daily
1.5 mg/kg intravenously every 6 hours; maximum 120 mg per dose.
None Documented
None Documented
Terminal half-life: 12-15 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is 2.5–3.5 hours in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment.
Renal: 30% unchanged; Biliary/fecal: 60% as metabolites; 10% other
Approximately 90% of absorbed dose excreted renally as unchanged drug; <5% in feces via biliary elimination.
Category C
Category C
Antiseptic
Antiseptic